
BMJ Open Development of a framework on the incorporation of real-world evidence (RWE) into cancer drug funding decisions in Canada: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration

Kelvin Kar-Wing Chan ,^{1,2,3} Pam Takhar ,^{2,4} William K Evans,⁵ Rebecca E Mercer ,^{2,3} Avram Denburg ,^{6,7} Jaclyn Beca,⁸ Caroline Muñoz,^{2,4} Scott Gavura,⁴ Winson Y Cheung,^{2,9,10} Jeffrey Hoch,^{6,11} Erica Craig,¹² Claire de Oliveira ,^{2,6,13} Marc Geirnaert,¹⁴ Maureen Trudeau,³ Tarry Ahuja,¹⁵ Stuart Peacock,^{2,16} Wei Fang Dai,^{1,2} Wanrudee Isaranuwatchai ,^{6,17} Yvonne Bombard ,^{6,18} Carole Chambers,¹⁹ Craig C Earle,^{1,3} Riaz Alvi,²⁰ Petros Pechlivanoglou,²¹ Mina Tadrous^{22,23}

CanREValue

- The Canadian Real-World Evidence for Value in Cancer (CanREValue) Collaboration established due to growing interest in using real world evidence (RWE) to support health technology assessment.
- CanREValue developed a framework to generate the use of RWE to inform cancer funding decisions.

CanREValue framework

- The goal of the framework was to facilitate the use of RWE by Canadian decision-makers for:
 - i) The reassessment of cancer drugs
 - ii) The refinement of funding decisions and the negotiation of drug prices.


Working Groups

5 working groups formed:


- 1) RWE Planning and Drug Selection working group
- 2) RWE Data working group
- 3) RWE methods working group
- 4) RWE reassessment and update working group
- 5) Engagement working group

CanREValue RWE Framework



Pre-Funding




Funding



Re-assessment & Uptake of Evidence



Legend



Criterion 1: Uncertainties in the clinical benefit and/or alignment with patient values*

Criterion 2: Uncertainties in value for money or feasibility of adoption of the drug*

At least one criterion has to be met in order to proceed to Criterion 3.

Not suitable for reassessment review

Criterion 3: The identified uncertainties listed in Criterion 1 and 2 are not expected to be resolved by evidence from future planned studies*

Not suitable for reassessment review

Criterion 4: Can the question/uncertainties potentially be answered by available data and methods?

Not suitable for reassessment review

Criterion 5: Can the study potentially be completed in a reasonable timeframe?

Not suitable for reassessment review

Proceed to prioritization process

Legend

- No, not suitable for reassessment review
- Yes, suitable for reassessment review




Figure 3 Phase II: Initiating and planning an RWE study. RWE, real-world evidence.